|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for BAZ2A |
 Gene summary |
| Basic gene Info. | Gene symbol | BAZ2A |
| Gene name | bromodomain adjacent to zinc finger domain, 2A | |
| Synonyms | TIP5|WALp3 | |
| Cytomap | UCSC genome browser: 12q13.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001300905.1, NM_013449.3, | |
| Description | TTF-I interacting peptide 5TTF-I-interacting protein 5bromodomain adjacent to zinc finger domain protein 2Atranscription termination factor I-interacting protein 5 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 605682 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000076108 | ||
| HPRD : 10417 | ||
| Vega : OTTHUMG00000170332 | ||
| Protein | UniProt: Q9UIF9 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_BAZ2A | |
| BioGPS: 11176 | ||
| Pathway | NCI Pathway Interaction Database: BAZ2A | |
| KEGG: BAZ2A | ||
| REACTOME: BAZ2A | ||
| Pathway Commons: BAZ2A | ||
| Context | iHOP: BAZ2A | |
| ligand binding site mutation search in PubMed: BAZ2A | ||
| UCL Cancer Institute: BAZ2A | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for BAZ2A |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | S1828 | V1827L | BRCA | 1 | D1688 | N1687D | COAD | 1 | C1682 | R1683G | SKCM | 1 | C1682 | R1683Q | STAD | 1 | C1697,D1695 | G1696R | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for BAZ2A |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | C1682 | R1683G | -1.9230228 | C1682 | R1683Q | -1.7541677 | S1828 | V1827L | -0.96896196 | D1688 | N1687D | -0.68673412 | C1697 | G1696R | -0.68552999 | D1695 | G1696R | -0.68552999 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for BAZ2A from PDB |
| Top |
| Differential gene expression and gene-gene network for BAZ2A |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for BAZ2A |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0033578 | Prostatic Neoplasms | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for BAZ2A |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of BAZ2A go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | ZN | ZINC(2+) | 4q6f | A | C1682 | ZN | ZINC(2+) | 4q6f | B | C1682 | ZN | ZINC(2+) | 4q6f | C | C1682 | ZN | ZINC(2+) | 4q6f | D | C1682 | ZN | ZINC(2+) | 4qf2 | A | C1682 | ZN | ZINC(2+) | 4qf2 | B | C1682 | ZN | ZINC(2+) | 4qf2 | C | C1682 | ZN | ZINC(2+) | 4qf2 | D | C1682 | ZN | ZINC(2+) | 4q6f | A | C1697 | ZN | ZINC(2+) | 4q6f | B | C1697 | ZN | ZINC(2+) | 4q6f | C | C1697 | ZN | ZINC(2+) | 4q6f | D | C1697 | ZN | ZINC(2+) | 4qf2 | A | C1697 | ZN | ZINC(2+) | 4qf2 | B | C1697 | ZN | ZINC(2+) | 4qf2 | C | C1697 | ZN | ZINC(2+) | 4qf2 | D | C1697 | III | Peptide ligand (ALA,ARG,THR,LYS) | 4q6f | C | D1688 | III | Peptide ligand (ALA,ARG,THR,LYS,GLN) | 4q6f | A | D1688 D1695 | III | Peptide ligand (ALA,ARG,THR,LYS,GLN) | 4q6f | B | D1688 D1695 | III | Peptide ligand (GLY,ALA,LYS,ARG,HIS,ARG,LYS,VAL,LEU) | 4qbm | A | S1828 |
| Top |
| Conservation information for LBS of BAZ2A |
| Multiple alignments for Q9UIF9 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |